Organigram Global Inc. · TSX:OGI
Organigram Global — Q3 2026 Earnings Presentation
23 slides from Organigram Global's earnings presentation, Aug 11, 2026
Slide 1: Investor Presentation
Investor Presentation March 31, 2026
Slide 2: Cautionary Statement
CAUTIONARY STATEMENT This document is current as of March 31, 2026, except where otherwise "financial outlook" within the meaning of applicable securities legislation. comparable. The most directly comparable measure to adjusted EBITDA stated. The information contained in this presentation is provid
Slide 3: Canadian Roots. Naturally Global.
Canadian Roots. Naturally Global. 13 YEARS OF WORLD CLASS INNOVATION GLOBAL RAPID RESPONSIBLE CAPABILITIES TRAILBLAZER STRATEGY INTERNATIONAL LEADERSHIP EXPANSION Founded in 2013, Organigram operates five Organigram is a leader In April 2026, Organigram Organigram exports Organigram transitioned adv
Slide 4: Canada's #1 LP in market
MILLED VAPES CONCENTRATES FLOWER Canada’s #1 #1 #1 #1 LP in market share1 PRE-ROLLS (including IPRs) FLOWER (including milled) EDIBLES RECREATIONAL MARKET #2 #2 #3 1. Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of March, 2026.
Slide 5: State-of-the-art Facilities
State-of-the-art Facilities Canada’s largest indoor cultivation Winnipeg, MB Aylmer, ON London, ON Lac-Supérieur, QC Moncton, NB • Edibles facility with Advanced capabilities & • Centralized distribution hub to • Producing hang-dried, hand- • Three-tiered, modular, strain-specific automated cutting-
Slide 6: Moncton Spotlight: Canada's Largest Indoor Facility
Moncton Spotlight: Canada's Largest Indoor Facility Canada largest indoor cultivation 500,000 square-foot Each cultivation room In-house R&D labs Implementing automation facility with 144 grows vertically on advancing genetic across production verticals modular and climate- three tiers, maximizing s
Slide 7: Coast to Coast Canadian Leadership by Market Share
Coast to Coast Canadian Leadership by Market Share # 1 WESTERN CANADA # 1 EASTERN CANADA 1 # CENTRAL CANADA WINNIPEG MONCTON LAC SUPÉRIEUR LONDON & AYLMER Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of March, 2026
Slide 8: Fiscal YTD Highlights
Fiscal YTD Highlights In millions unless otherwise indicated +14% +18% +200 bps $123.3 $11.1 $9.4 32% 34% $108.3 H1 '25 H1 '26 H1 '25 H1 '26 H1 '25 H1 '26 Net Revenue International Sales Adjusted Gross Margin1 Closed acquisition of Sanity Group. Expanded branded international Expanded cultivation ca
Slide 9: Sanity Group Acquisition
Sanity Group Acquisition1 Organigram completed its acquisition of one of Germany's cannabis leaders, Sanity Group, in April 2026 to become the only pure-play cannabis company with leadership positions in the world's two largest federally legal markets, Canada and Germany. Organigram is #1 in Adult-U
Slide 10: Expanding International Distribution
Expanding International Distribution • Through its acquisition of Sanity • Exporting medical whole flower Group, Organigram supplies to multiple customers medical flower to Germany, the • Launched branded vape and UK, Czechia, Poland, and edibles sales in Q2 Fiscal 2026 operates two recreational Swi
Slide 11: Portfolio of Brands
Portfolio of Brands Delivering strong coverage across all segments and categories — now expanding into Europe with the Sanity portfolio. New PREMIUM REC New New New MAINSTREAM Vayamed avaay MED REC CBD MED New New VALUE MED MED Flower Milled Pre-Rolls Infused Pre-Rolls Vapes Beverages Edibles Hash C
Slide 12: Canadian brands and FAST nanoemulsion technology
• Award-winning mainstream brand • #1 concentrates and #2 Canadian vape Premium • • #2 innovation flower brand brand1 in Canada • Now leveraging FAST nanoemulsion brand by market share1 First Organigram • • Focused brand tocatering on larger formats launch to technology for ingestible products • Por
Slide 13: US Portfolio
US PORTFOLIO1 • Gummy brand offering low THC + • Award winning sparkling juices and • Value-priced soda brand with top selling functional ingredients like caffeine, lemonades flavours like cola, lemon-lime and cream chamomile extract and l-theanine to • Supports the arts community soda target specif
Slide 14: Strategic Partnership with BAT
Strategic Partnership with BAT: 2026 2024 2021 $221 Million $125 Million $65 Million • Established the PDC with formation of a • Creation of strategic investment pool • Financing provided to support acquisition of Center of Excellence at Moncton campus named Jupiter, funded with $83.1 million Sanity
Slide 15: U.S. Investments
U.S. Investments MANUFACTURING & FORMULATION SEED-BASED TECHNOLOGY • US$10 million investment into U.S.-based Phylos to access flower-derived minor cannabinoids such as • U.S.$2 million investment into THCV and initiate the conversion of a portion of U.S.-based OBX.1 Organigram’s garden to more cost
Slide 16: Seeds: More Robust and Uniform
Seeds: More Robust and Uniform Uniformity and Robustness of Seed Grow Clones Seeds
Slide 17: Q2 F'26 Revenue and Margins
Q2 F'26 Revenue and Margins 38% 36% 37% 34% 33% 33% $123.3 38% 31% $110.2 $97.3 $ $102.8 $93.3 $69.9 $63.6 $ $66.8 $80.1 $65.6 $70.8 $44.7 $63.5 $59.8 $42.7 $41.1 $30.6 $21.9 $24.2 $23.9 $18.4 $14.6 $16.5 $14.3 Q3 F24 Q4 F24 Q1 F25 Q2 F25 Q3 F25 Q4 F25 Q1 F26 Q2 F26 In millions 1 1 Net Revenue Gross
Slide 18: Q2 F'26 International Sales
Q2 F'26 International Sales $9.6 $7.4 $6.1 $6.1 • International sales trajectory expected to be $5.0 accelerated by integration of $4.1 Sanity Group $3.3 • EU-GMP certification of $2.4 Moncton in progress, expected to increase sales and margins Q3 F24 Q4 F24 Q1 F25 Q2 F25 Q3 F25 Q4 F25 Q1 F26 Q2 F26
Slide 19: Q2 F'26 Adjusted EBITDA
Q2 F'26 Adjusted EBITDA1 $9.8 $5.9 $5.7 $5.3 $4.9 $3.5 $1.4 $0.9 Q3 F24 Q4 F24 Q1 F25 Q2 F25 Q3 F25 Q4 F25 Q1 F26 Q2 F26 In millions 1. Adjusted EBITDA is a non-IFRS financial measures not defined by and does not have any standardized meanings under IFRS"), as issued by the International Accounting
Slide 20: Balance Sheet
Balance Sheet Q2 Fiscal 2026: $54.8 million1 $4.3 million Total cash Unrestricted cash (including restricted cash & short-term investments) Subsequent to Q2 F'26 Organigram: $60 million Loan Facility • $20 million non-revolving term facility used to partially fund Sanity Group acquisition • $30 mill
Slide 21: Q2 FY26 Select Financial Metrics
Q2 FY26 Select Financial Metrics In 000’s unless otherwise indicated Select Key Financial Metrics (in $000s unless otherwise indicated) Q2-2026 Q2-2025 % Change Gross revenue 93,250 102,763 (9)% Excise taxes (33,456) (37,163) (10)% Net revenue 59,794 65,600 (9)% Cost of sales 44,800 45,813 (2)% Gros
Slide 22: Q2 FY26 Select Balance Sheet Metrics
Q2 FY26 Select Balance Sheet Metrics In 000’s unless otherwise indicated Select Balance Sheet Metrics (in $000s) March 31, 2026 December 31, 2025 % Change Cash & short-term investments (including restricted cash) 54,754 84,420 (35)% Biological assets & inventories 135,158 123,954 9% Other current as
Slide 23: Capital Structure
Capital Structure In 000’s unless otherwise indicated Capital Structure March 31, 2026 May 7, 2026 Common shares issued and outstanding 136,468 140,775 Preferred shares1 13,794 49,204 Options (Weighted Average Exercise Price: $10.20) 2,130 2,802 Warrants (Exercise Price: $3.65) 4,451 4,450 Top-up ri